TGM2 and cranioectodermal dysplasia: Duodenal biopsies were collected from 58 individuals with CeD before (GFD) and after a 6-week gluten challenge combined with treatment with 100 mg of the TG2 inhibitor ZED1227 per day (postgluten challenge drug (PGCd); n = 34) or placebo (PGC placebo (PGCp); n = 24).